The part I liked the most: 'constructing a pipeline of Phase 2 ready projects that address a large commercial market, are relatively inexpensive to run and are relatively short duration.'
And in answer to the flanostu's comment in other thread, I think I found my answer: 'The final step post a successful capital raising, is that Gleneagle will change its name to Zelda Therapeutics Ltd, with timing likely to be in March 2016.'
